Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials

Mittendorf, Elizabeth A.; Alatrash, Gheath; Xiao, Huamei; Clifton, Guy T.; Murray, James L.; Peoples, George E.

doi:10.1586/erv.11.59

Cited by 15 publications

(6 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these antibodies are effective approaches only for patients whose tumors overexpress the human epidermal growth factor receptor 2 (HER2) antigen. For those patients without the HER2 antigen, these antibodies might not be useful (Coussens and Werb, 2002;Combadiere and Mahe, 2008;Mittendorf et al, 2011;Berger and Wunderink, 2013;Mattheolabakis et al, 2016). Therefore, a vaccine for breast cancer has been explored as an alternative to support the unmet needs of such patients, such as a particulate vaccine delivered via the skin, which was found to be a better route of immunization in a murine model (Weitzman and Gordon, 1990).The vaccines mentioned above were shown to be effective in cancer immunotherapy.…”

Section: Immunitymentioning

confidence: 99%

“…Therefore, a vaccine for breast cancer has been explored as an alternative to support the unmet needs of such patients, such as a particulate vaccine delivered via the skin, which was found to be a better route of immunization in a murine model (Weitzman and Gordon, 1990).The vaccines mentioned above were shown to be effective in cancer immunotherapy. Therefore, new cancer vaccines would greatly progress the treatment of cancer (Mattheolabakis et al;Mittendorf et al;Coussens and Werb, 2002;Combadiere and Mahe, 2008;Berger and Wunderink, 2013;Chablani et al, 2019;Garbuglia et al, 2020).…”

Section: Immunitymentioning

confidence: 99%

See 1 more Smart Citation

Microbes in Tumoral In Situ Tissues and in Tumorigenesis

Xue

Han

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Cancerous tumors are severe diseases affecting human health that have a complicated etiology and pathogenesis. Microbes have been considered to be related to the development and progression of numerous tumors through various pathogenic mechanisms in recent studies. Bacteria, which have so far remained the most studied microbes worldwide, have four major possible special pathogenic mechanisms (modulation of inflammation, immunity, DNA damage, and metabolism) that are related to carcinogenesis. This review aims to macroscopically summarize and verify the relationships between microbes and tumoral in situ tissues from cancers of four major different systems (urinary, respiratory, digestive, and reproductive); the abovementioned four microbial pathogenic mechanisms, as well as some synergistic pathogenic mechanisms, are also discussed. Once the etiologic role of microbes and their precise pathogenic mechanisms in carcinogenesis are known, the early prevention, diagnosis, and treatment of cancers would progress significantly.

show abstract

Section: Immunitymentioning

confidence: 99%

Section: Immunitymentioning

confidence: 99%

Microbes in Tumoral In Situ Tissues and in Tumorigenesis

Xue

Han

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Regarding delivery systems, antigens can be delivered via viral vectors [14], non-viral vectors [15], inactivated tumor cells [16,17], protein or peptide-pulsed antigen presenting cells [18,19], or loaded in targeted and/or controlled-release technologies [20]. In addition, each of the aforementioned ASIs can be supplemented with cytokines or other immunomodulators [9,19,21]. …”

Section: A New Era Of Immunotherapymentioning

confidence: 99%

“…Vaccines comprised of multiple epitopes potentiate a polyclonal response capable of responding to a more diverse population of tumor cells [9,21]. In addition, because all of the potential antigens are derived from a patient's own tumor, ATCVs are patient-specific.…”

Section: Advantages Of Autologous Tumor Cell-based Vaccinesmentioning

confidence: 99%

Current status of autologous breast tumor cell-based vaccines

Kurtz

Ravindranathan

Zaharoff³

2014

Expert Review of Vaccines

View full text Add to dashboard Cite

Summary Approximately 9 of 10 breast cancer-related deaths are attributable to metastasis. Yet, less than 4% of breast cancer patients are initially diagnosed with metastatic cancer. Therefore, the majority of breast cancer-related deaths are due to recurrence and progression of nonmetastatic disease. There is tremendous clinical opportunity for novel adjuvant strategies, such as immunotherapies, that have the potential to prevent progressive recurrences. In particular, autologous tumor cell-based vaccines can train a patient's immune system to recognize and eliminate occult disease. Autologous tumor cell-based vaccines have several advantages including safety, multivalency and patient specificity. Furthermore, because lumpectomy or mastectomy is indicated for the vast majority of breast cancer patients, resected tumors offer a readily available, patient-specific source of tumor antigen. Disadvantages of autologous tumor cell-based vaccines include poor immunogenicity and production inconsistencies. This review summarizes recent progress in the development of autologous breast tumor vaccines and offers insight for overcoming existing limitations.

show abstract

“…The Her-2/neu cell surface oncoprotein is an interesting target for immunotherapy, Her-2/neu positive breast cancer patients have poor prognosis [90], they can be treated with humanized antibodies, and there are many vaccine protocols under evaluation [91]. In an experimental mammary cancer model, human Hsp70 was fused to the extracellular C-terminal domain of rat Her-2/neu, this DNA vaccine could significantly increased survival and reduced metastasis [92].…”

Section: Preclinical Studies (Animal Models)mentioning

confidence: 99%

Heat Shock Proteins (HSPs) Based Anti-Cancer Vaccines

Ciocca

Cayado-Gutiérrez²,

Maccioni³

et al. 2012

CMM

View full text Add to dashboard Cite

The importance of HSPs themselves in antigen presentation and cross-presentation remains controversial. Most studies agree that as part of their molecular chaperone function, HSPs can bind and present tumor associated antigens to professional antigen presenting cells through MHC class I and class II molecules, leading to the activation of anti-tumor CD8+ and CD4+ T cells. The regulation of the innate and adaptive immune responses by HSPs is still a matter of intense research. HSPs are seen as important anticancer vaccine adjuvants. They are used through different delivery systems: HSPs/antibodies, peptide/protein-HSP complexes, tumor antigen/HSP gene fusion, viral peptides/HSP complexes or gene fusion, viral proteins/bacterial HSP fusion. In preclinical models different administration routes, subcutaneous, intradermal, intramuscular or even peroral (under special conditions) can be used, and the animal toxicities are non-significant. The HSP-based vaccines can induce specific and non-specific cellular immune responses all of which are important to induce tumor rejection. In addition, the antibodies generated after vaccination are emerging as important protagonist in the antitumoral response. This response is significantly enhanced when the suppressive tumor microenvironment and the immune suppressing effector cells are blocked. Several clinical studies have been carried out and are ongoing, immunizing cancer patients with autologous tumor derived HSP-peptide complexes (HSPPCs). The most promising results have been observed in patients with melanoma and renal clear cell cancer without advanced disease. There are clinical trials with HSP-based anticancer vaccines other than with HSPPCs (including patients with non-Hodgkin lymphoma, high-grade transitional cell carcinoma of the bladder, high-grade cervical dysplasia, etc).

show abstract

Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials

Cited by 15 publications

References 96 publications

Microbes in Tumoral In Situ Tissues and in Tumorigenesis

Microbes in Tumoral In Situ Tissues and in Tumorigenesis

Current status of autologous breast tumor cell-based vaccines

Heat Shock Proteins (HSPs) Based Anti-Cancer Vaccines

Contact Info

Product

Resources

About